To assess the prognostic value of matrix Gla protein (MGP) expression in cases of breast cancer, 9 samples from patients diagnosed with breast cancer who were followed up for more than 10 years were microdissected and then analyzed using Affymetrix U133 Plus 2.0 Arrays. Genes that exhibited significant differences in expression between patients with a good prognosis and those with a poor prognosis were identified. The MGP gene was among the genes up-regulated in cases where the prognosis was poor, indicating that the mRNA levels of MGP are a potential prognostic indicator of breast cancer. However, immunohistostaining of breast tissue microarrays (n=207) did not reveal a correlation between the protein expression of MGP and overall survival, neither was there a correlation between the protein expression of MGP and ER status or bone metastasis. In breast cancer cases, the mRNA level of MGP may be a marker indicating poor prognosis; however, protein expression determined by immunohistostaining is not.
Introduction
Matrix Gla protein (MGP) is a calcium-binding protein isolated from bone matrix and cartilage that requires vitamin Kdependent Á-carboxylation (1) (2) (3) . In addition to its presence in bone or cartilage, MGP is distributed in organs such as the lung, heart, kidney and spleen (4) . Mutations in the MGP gene are noted in Keutel Syndrome (5), a rare condition characterized by ectopic calcification and ossification, peripheral stenosis of the pulmonary artery and midfacial hypoplasia. It has been suggested that the function of MGP in bone and cartilage is to inhibit the formation of hydroxyapatite.
The role of MGP in oncogenesis is unclear, and the correlation between MGP expression and cancer differs according to tumor type. MGP mRNA expression that was increased in comparison to normal tissue levels was found in ovarian cancer (6) and renal cell carcinoma (7) . In renal cell carcinoma, a significant inverse correlation was observed between the level of MGP expression and tumor size, lymph node metastasis and tumor grade. In contrast, the expression of MGP mRNA was down-regulated in colorectal cancer cells compared to adjacent normal tissue, though this down-regulation was not correlated with histopathologic features, such as tumor progression, size and cell differentiation (8) . MGP mRNA levels were significantly increased in high-compared to low-grade astrocytic gliomas (9) .
In breast cancer, a study using cDNA hybridization revealed the expression of MGP to be 20-fold higher in the human metastatic breast cancer cell line 600PEI than in normal breast epithelium (10) . In this study, we found MGP to be overexpressed in breast cancer patients with a poor prognosis compared to those with a good prognosis, on the basis of gene expression analysis using microarrays. We then used the tissue microarrays to clarify whether MGP protein levels determined by immunohistostaining could serve as a prognostic marker of breast cancer, and analyzed the correlation between MGP and ER status or bone metastasis. The microarray data were analyzed using R software (http://www.r-project.org/). Expression data were normalized by the Robust Multichip Average (RMA) method (12) using Bioconductor and associated packages (Bioconductor 2.6.1, http://www.bioconductor.org). The data were then log 2 -transformed. Genes expressed differently between the poor and good prognosis groups were identified using the Significance Analysis of Microarrays (SAM) method with a fold change cutoff >3.5 (up-regulated in the poor prognosis group) or <0.4 (down-regulated); p-value <0.01 (13).
Materials and methods

Breast
Real-time RT-PCR analysis.
Expression of MGP was quantified by real-time RT-PCR. The templates and primer set were mixed with 2X QuantiTect SYBR-Green PCR Master Mix (Qiagen). ß-actin was used as a control. Reactions were performed in triplicate in 96-well microtiter plates in an ABI PRISM 7900HT (Applied Biosystems, Foster City, CA, USA). Primer sequences for MGP were 5'-GCTCAATAGGGAAG CCTGTGAT-3' (forward primer) and 5'-TTTCTTCCCTCA GTCTCATTTGG-3' (reverse primer); primer sequences for ß-actin were 5'-TCACCCACACTGTGCCCATCTACGA-3' and 5'-CAGCGGACCGCTCATTGCCAATGG-3'.
Tissue microarray. TMAs of 207 breast cancer cases with at least two cores of 2 mm in diameter were made by punching out of the donor block and transferring to a recipient block according to the manufacturer's instructions using a dedicated TMA instrument (KIN-1, Azumayaikakikai, Tokyo, Japan).
Immunohistochemistry. Expression of MGP in breast cancer cells was validated by immunohistochemistry. Immunohistochemical analysis was performed according to the dextranpolymer method (EnVision+; Dako, Glostup, Denmark) using monoclonal antibodies against MGP (Proteintech Group Inc., Chicago, IL, USA; 1:100). Heat-induced antigen retrieval pretreatments were performed with Target Retrieval Solution (Dako). Antibody binding was scored in a blinded fashion by two pathologists. A score of 1 was assigned when ≥5% of the neoplastic cells were definitely positive and a score of 0 when <5% of tumor cells were stained (Fig. 1) .
Statistical analysis. Survival curves were plotted according to the Kaplan-Meier method and compared using log-rank tests by Statistica 5.5. Univariate and multivariate analyses of prognostic indicators of overall survival were performed using the Cox proportional hazards regression model with R software. Variables that were statistically significant at p<0.05 were retained in the model.
Results
Gene expression analysis. The characteristics of the patients included in the gene expression microarray are summarized in Table I . We selected genes that were differentially expressed between the good prognosis group (overall survival >10 years) and the poor prognosis group (overall survival <10 years), and obtained 18 up-regulated (FC>3.5; p<0.01) and 23 downregulated (FC<0.4; p<0.01) genes in the poor prognosis group (Table II) . MGP was among the genes overexpressed in the poor prognosis group (FC=9.25, p=0.0012), and had the lowest p-value for discriminating between the two groups. Moreoever, the differential expression of MGP was determined by two probe sets (ID 238481_at and 202291_s_at) .
Confirmation of differential expression.
To confirm the results of gene expression microarray analysis, we carried out Table I . Clinical and histopathological characteristics of breast cancer patients involved in the microarray analysis. 
LN, lymph node metastasis; ER, estrogen receptor; PgR, progesteron receptor; CMF, cyclophosphamide, doxorubicin and fluorouracil; 5'-DFUR, 5'-deoxy-5-fluorouridine; EXE, exemestane; TAM, tamoxifen.
-----------------------------------------------------------------------------------------------------
real-time quantitative RT-PCR for the MGP gene and the quantitative control gene, ß-actin. Expression levels quantified by real-time RT-PCR were highly correlated with those determined by gene expression microarray analysis (Pearson rank correlation; r=0.914), confirming the reliability of our microarray experiments (Fig. 2) . ß-actin was used as a reference gene, because it was the gene with the least fluctuation in our samples according to the microarray data. Expression of MGP was significantly higher in the poor than in the good prognosis group according to RT-PCR data (p<0.01). MGP mRNA levels were increased >3-fold in all the patients in the poor prognosis group, as compared to the mean expression level of the good prognosis group. The highest up-regulation of MGP observed was a 12-fold increase, as shown in Fig. 2 . Based on the above findings, MGP was selected for further analysis.
Immunohistochemical analysis. MGP expression was examined in 207 breast cancer specimens by immunohistochemistry. The clinical and histopathological characteristics are listed in Table III . In the immunohistochemical evaluation, 104 patients had a score of 0 and 103 a score of 1. We tested for associations between the stainings and overall survival. KaplanMeier overall survival curves are shown in Fig. 3 . A score of 1 was not associated with a poor prognosis compared to a score of 0 (log rank, p=0.79).
Regarding the correlation between MGP expression and ER status, the ER-positive rate was 60.6% for a score of 0 and 60.2% for a score of 1. MGP protein expression was not related to ER status (¯2 test, p=0.34). The bone metastasis rate was 17.3% for a score of 0 and 12.6% for a score of 1. MGP protein expression was not related to bone metastasis (¯2 test, p=0.96).
Discussion
Gene expression analysis revealed the mRNA level of MGP to be much higher in breast cancer patients with a poor prognosis than in those with a good prognosis. To investigate the utility of MGP protein expression as a prognostic marker of breast cancer, we examined the correlation between MGP protein expression and overall survival using tissue microarrays. First, the percentage of stained tumor cells, -5, -25, -50, -75, or -100%, was determined, then the correlation between each of these groups and overall survival was analyzed. No difference between the groups was observed, and the correlation between MGP and overall survival was not confirmed.
A correlation between MGP expression and tumor development or tumor progression has been reported in ovarian cancer, renal cell carcinoma, colorectal cancer and glioma (6-9). There have also been several reports of the upregulation of MGP mRNA expression in human breast cancer cell lines (10,14). Table II . Differentially expressed genes in the good and poor prognosis groups.
Gene symbol Accession no. ----------------------------------------------------------------------------------------------------- In this study, using both microarray analysis and quantitative RT-PCR, we found that the mRNA of MGP was overexpressed in patients with a poor prognosis. This indicated that the mRNA levels of MGP could be a prognostic factor for breast cancer. However, we could not establish a correlation between the protein levels of MGP and overall survival. The reason for the difference in results regarding the mRNA and protein levels of MGP is unclear, though further study of the function of MGP may elucidate these findings. Estrogen has been found to strongly induce MGP gene expression in ERpositive breast cancer cells (14) . However, in the present study, MGP expression was not significantly affected by ER status.
In summary, MGP mRNA expression was up-regulated in breast cancer patients with a poor prognosis, and may have the potential to serve as a prognostic indicator of the disease; however, no correlation was established between the protein levels of MGP as determined by immunohistostaining and overall survival. Table III . Clinical and histopathological characteristics of the breast cancer patients. 
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